Lucid Diagnostics Inc
LUCD1.035USD
+0.035+3.50%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
87.33MCap. mercado
PérdidaP/E TTM
Más Datos de Lucid Diagnostics Inc Compañía
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.
Información de la empresa
Símbolo de cotizaciónLUCD
Nombre de la empresaLucid Diagnostics Inc
Fecha de salida a bolsaOct 14, 2021
Director ejecutivoDr. Lishan Aklog, M.D.
Número de empleados72
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 14
Dirección360 Madison Avenue
CiudadNEW YORK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal10017
Teléfono12129494319
Sitio Webhttps://www.luciddx.com/
Símbolo de cotizaciónLUCD
Fecha de salida a bolsaOct 14, 2021
Director ejecutivoDr. Lishan Aklog, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.47M
-4.86%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
Chief Financial Officer
Chief Financial Officer
1.32M
-5.38%
Mr. Dennis Matheis, CPA
Mr. Dennis Matheis, CPA
Independent Director
Independent Director
462.80K
+310.28%
Dr. James L. Cox
Dr. James L. Cox
Independent Director
Independent Director
282.12K
-6.47%
Mr. Stanley N. Lapidus
Mr. Stanley N. Lapidus
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
214.39K
-8.34%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
197.46K
-53.33%
Dr. Jacque J. Sokolov, M.D.
Dr. Jacque J. Sokolov, M.D.
Independent Director
Independent Director
197.46K
-8.99%
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.47M
-4.86%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
Chief Financial Officer
Chief Financial Officer
1.32M
-5.38%
Mr. Dennis Matheis, CPA
Mr. Dennis Matheis, CPA
Independent Director
Independent Director
462.80K
+310.28%
Dr. James L. Cox
Dr. James L. Cox
Independent Director
Independent Director
282.12K
-6.47%
Mr. Stanley N. Lapidus
Mr. Stanley N. Lapidus
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
214.39K
-8.34%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
197.46K
-53.33%
Desglose de ingresos
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
828.00K
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 24 de may
Actualizado: sáb., 24 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
PAVmed Inc
28.93%
Masters Capital Management, L.L.C.
2.52%
Alyeska Investment Group, L.P.
1.74%
Aklog (Lishan)
1.36%
McGrath (Dennis M)
1.22%
Other
64.23%
Accionistas
Accionistas
Proporción
PAVmed Inc
28.93%
Masters Capital Management, L.L.C.
2.52%
Alyeska Investment Group, L.P.
1.74%
Aklog (Lishan)
1.36%
McGrath (Dennis M)
1.22%
Other
64.23%
Tipos de accionistas
Accionistas
Proporción
Corporation
28.93%
Hedge Fund
7.03%
Individual Investor
5.61%
Investment Advisor
2.15%
Investment Advisor/Hedge Fund
0.79%
Research Firm
0.18%
Other
55.31%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
94
48.34M
44.68%
+6.89M
2025Q1
87
48.55M
48.13%
+9.11M
2024Q4
72
40.61M
68.54%
+2.85M
2024Q3
67
37.54M
71.75%
+1.52M
2024Q2
80
37.13M
71.19%
+1.04M
2024Q1
96
36.05M
80.31%
-3.56M
2023Q4
96
34.89M
79.71%
-1.40M
2023Q3
97
35.04M
80.14%
-1.22M
2023Q2
93
35.02M
80.10%
-1.13M
2023Q1
94
35.12M
89.38%
+2.48M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
PAVmed Inc
31.30M
28.93%
--
--
Dec 06, 2024
Masters Capital Management, L.L.C.
2.73M
2.52%
+2.73M
--
Mar 31, 2025
Alyeska Investment Group, L.P.
1.89M
1.74%
+1.89M
--
Mar 31, 2025
Aklog (Lishan)
1.47M
1.36%
-75.00K
-4.86%
Apr 22, 2025
McGrath (Dennis M)
1.32M
1.22%
-75.00K
-5.38%
Apr 22, 2025
Ayrton Capital LLC
1.20M
1.11%
+1.18M
+7216.46%
Dec 31, 2024
The Vanguard Group, Inc.
888.87K
0.82%
+327.96K
+58.47%
Mar 31, 2025
O'Neil (Shaun)
826.76K
0.76%
-50.00K
-5.70%
Apr 22, 2025
Gordon (Michael Adam)
700.00K
0.65%
-183.33K
-20.75%
Apr 22, 2025
Matheis (Dennis)
462.80K
0.43%
+350.00K
+310.28%
May 22, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.02%
iShares Core S&P Total U.S. Stock Market ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Russell 2000 Value ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proporción0.02%
iShares Core S&P Total U.S. Stock Market ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
iShares Russell 2000 Growth ETF
Proporción0%
iShares Russell 2000 Value ETF
Proporción0%
Global X Russell 2000 ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
